Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
FP13 - Immunotherapy (Phase II/III Trials)
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Immunotherapy (Phase II/III Trials)
-
+
FP13.02 - Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189
00:00 - 00:00 | Presenter: Jhanelle Elaine Gray
- Abstract
Loading...
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P76.57 - Resistance Mechanisms to Osimertinib Upon it’s Line of Therapy in Patients with EGFR+ NSCLC and Beyond
00:00 - 00:00 | Presenter: Vered Fuchs
- Abstract
Loading...
-
+
P84 - Targeted Therapy - Clinically Focused - ALK
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P84.03 - GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients
00:00 - 00:00 | Presenter: Nir Peled
- Abstract
Loading... -
+
P84.10 - The Impact of 3rd-Line ALK Inhibitors in ALK Positive NSCLC in Real-World Data
00:00 - 00:00 | Presenter: Mor Moskovitz
- Abstract
Loading...
-
+
P87 - Targeted Therapy - Clinically Focused - RET
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P87.01 - Higher Dose Alectinib for Advanced RET+ NSCLC: Results from the RET+ Cohort of the Blood First Assay Screening Trial (BFAST)
00:00 - 00:00 | Presenter: Nir Peled
- Abstract
Loading...
-
+
IS09 - Industry Symposium Sponsored by Pfizer Oncology: Expert Question Time: ALK+ NSCLC
- 13:00 - 14:00
- 1/29/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS09.02 - The Future of ALK+ NSCLC
13:45 - 13:45 | Presenter: Nir Peled
- Abstract
No abstract available for this presentation
